Abstract Library

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4514 Liver debulking surgery is benefit to PFS in patients with high tumour burden of neuroendocrine tumour liver metastases

Introduction: Liver debulking surgery has shown its definite effect on prolonging survival in patients with neuroendocrine tumour liver metastases (NETLM). However, the effect of liver debulking surgery on the high burden of NETLM is still not clear.

Conference:

Presenting Author:

Authors: Zhou J, Liang Y, Chen J, Wang L,

Keywords: liver debulking surgery, NETLM,

#4348 Real-world clinicopathological features and outcome of elderly patients with thymic neuroendocrine neoplasms: A retrospective single-institution analysis

Introduction: Thymic neuroendocrine neoplasms (TNENs）are rare and heterogeneous diseases. With the aging of society, there has been an increase in the proportion of elderly patients with TNENs，however, research on these patients is limited.

Conference:

Presenting Author:

Authors: Jia X, Sun Z, Xu J, Huang D, Chen F,

Keywords: thymic neuroendocrine tumour, aged 65 years or above, clinicopathological characteristics, survival analysis, real-world,

#4346 Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumours: A 102-case retrospective study

Introduction: The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib’s efficacy in treating thymic neuroendocrine tumours (TNETs).

Conference:

Presenting Author:

Authors: Jia X, Sun Z, Xu J, Huang D, Chen F,

Keywords: neuroendocrine tumour, thymic, surufatinib, treatment,

#4285 Predictive biomarkers for immunotherapy efficacy in neuroendocrine neoplasms

Introduction: The application of immunotherapy in NENs is still in its early stages. Identifying reliable predictive biomarkers of efficacy is critical for research, enabling better selection of patients who are more likely to respond to immunotherapy and improving treatment success rates.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Sun Z, Jia X, Chen J,

Keywords: immunotherapy, biomarker, neuroendocrine neoplasm,